Premium
Intravenous anti‐D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy
Author(s) -
Michel Marc,
Novoa Maria V.,
Bussel James B.
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04567.x
Subject(s) - medicine , pregnancy , thrombocytopenic purpura , platelet , rh isoimmunization , fetus , immune system , gastroenterology , purpura (gastropod) , hematology , obstetrics , immunology , ecology , genetics , biology
Summary. This pilot study assessed the safety and efficacy of intravenous anti‐D in eight Rh(D)‐positive women with immune thrombocytopenic purpura (ITP) during the second and third trimesters of pregnancy. The median pretreatment platelet count was 28 × 10 9 /l. The patients received one to seven anti‐D infusions at a mean dose of 62·7 µg/kg, and the response rate to anti‐D was 75%. A haemoglobin decrease of > 2·0 g/dl occurred only once. Fetal hydrops was not identified by ultrasonography. The direct antiglobulin test was positive in three out of seven Rh + newborns, none of whom was anaemic or jaundiced. Anti‐D is effective and appears to be safe for both mother and fetus.